Hi Tony, You wrote; "The question is what strategic options are being considered? A merger and acquisition, strategic alliance or something else?"
We can look at Phenomica as a potential template for a transaction which could involve a cornerstone partner in synthetic biology. Recapping, Phylogica and Cambridge University spun off their collaborative work into a new corporate entity.
Stecyk specifically states that a partnership is being evaluated for other applications of the platform. I don't believe it will be M&A; first of all Phylogica has to build shareholder value.
Meanwhile, Phylogica will continue to develop its core human therapeutic alliances and in-house research albeit with a focus upon broad therapeutic discovery alliances.
Regards,
Wayne.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)